161 related articles for article (PubMed ID: 37808997)
1. Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.
Beillat M; Durand-Zaleski I; Pirenne F; Bénard S; Chillotti L; Galacteros F
Front Public Health; 2023; 11():1215605. PubMed ID: 37808997
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.
Leleu H; Arlet JB; Habibi A; Etienne-Julan M; Khellaf M; Adjibi Y; Pirenne F; Pitel M; Granghaud A; Sinniah C; De Montalembert M; Galacteros F
PLoS One; 2021; 16(7):e0253986. PubMed ID: 34242255
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
[TBL] [Abstract][Full Text] [Related]
4. Severity and burden of sickle cell disease in France: a nationwide real-world study.
Brousse V; Bernaudin F; Melaine A; Goguillot M; Gallagher M; Benard S; Habibi A
Haematologica; 2023 Sep; 108(9):2476-2486. PubMed ID: 36924235
[TBL] [Abstract][Full Text] [Related]
5. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
[TBL] [Abstract][Full Text] [Related]
6. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.
Lobo C; Moura P; Fidlarczyk D; Duran J; Barbosa R; Oliveira T; do Nascimento EM; Bhakta N; Hankins JS
BMC Health Serv Res; 2022 Jan; 22(1):42. PubMed ID: 34998394
[TBL] [Abstract][Full Text] [Related]
8. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
10. Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France.
Pourcher V; Gourmelen J; Bureau I; Bouee S
PLoS One; 2020; 15(12):e0243529. PubMed ID: 33332394
[TBL] [Abstract][Full Text] [Related]
11. Acute care utilization in pediatric sickle cell disease and sickle cell trait in the USA: prevalence, temporal trends, and cost.
Peterson EE; Salemi JL; Dongarwar D; Salihu HM
Eur J Pediatr; 2020 Nov; 179(11):1701-1710. PubMed ID: 32394268
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
13. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
[TBL] [Abstract][Full Text] [Related]
14. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
15. Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost.
Claudepierre P; Fagnani F; Cukierman G; de Chalus T; Joubert JM; Laurendeau C; Gourmelen J; Breban M
Joint Bone Spine; 2019 Jan; 86(1):69-75. PubMed ID: 29709699
[TBL] [Abstract][Full Text] [Related]
16. Sickle cell disease complications: Prevalence and resource utilization.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
PLoS One; 2019; 14(7):e0214355. PubMed ID: 31276525
[TBL] [Abstract][Full Text] [Related]
17. Migraine burden and costs in France: a nationwide claims database analysis of triptan users.
Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F
J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035
[No Abstract] [Full Text] [Related]
18. Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees.
Mahesri M; Schneeweiss S; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Desai RJ
Eur J Haematol; 2021 Feb; 106(2):273-280. PubMed ID: 33155319
[TBL] [Abstract][Full Text] [Related]
19. Preoperative blood transfusions for sickle cell disease.
Estcourt LJ; Kimber C; Trivella M; Doree C; Hopewell S
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003149. PubMed ID: 32614473
[TBL] [Abstract][Full Text] [Related]
20. Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents.
Reddy PS; Cai SW; Barrera L; King K; Badawy SM
Ann Med; 2022 Dec; 54(1):683-693. PubMed ID: 35234095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
